EcoDrugPlus

Somatostatin Receptor 2

Ensembl ID : ENSAOCG00000012953
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSAOCG00000002465
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSAOCG00000008494
Gene Symbol: SPHK2
3 Cross references
202 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSAOCG00000005582
Gene Symbol: S1PR1
3 Cross references
193 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSAOCG00000023208
Gene Symbol: SYK
3 Cross references
203 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSAOCG00000011107
Gene Symbol: LOC111563640
3 Cross references
211 Possible Orthologues:

Steroid 5 Alpha-Reductase 2

Ensembl ID : ENSAOCG00000003590
Gene Symbol: SRD5A2
3 Cross references
192 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSAOCG00000000068
Gene Symbol: SOAT1
3 Cross references
211 Possible Orthologues:

Substance-P Receptor-Like

Ensembl ID : ENSAOCG00000001477
Gene Symbol: LOC111574428
3 Cross references
194 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSAOCG00000008745
Gene Symbol: TACR1
3 Cross references
181 Possible Orthologues:

Tachykinin Receptor 2

Ensembl ID : ENSAOCG00000022739
Gene Symbol: TACR2
3 Cross references
200 Possible Orthologues:

Tachykinin Receptor 3

Ensembl ID : ENSAOCG00000008460
Gene Symbol: TACR3
4 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).